ASEAN Medical Device Directive Harmonization and Thailand

Manufacturers planning a multi-country ASEAN launch often ask a version of the same question: if a device is approved in one ASEAN country, does that shortcut approval everywhere else in the region? The honest answer is partial. The ASEAN Medical Device Directive gives Thailand and nine other member states a common classification system and a shared technical dossier format, and that shared foundation genuinely reduces duplicated work. It does not, however, replace Thailand's own national requirements, and manufacturers who assume otherwise tend to discover the gap late in their submission timeline.

What the AMDD Actually Is

The ASEAN Medical Device Directive, signed by member states in 2015, was developed under the ASEAN Medical Device Product Working Group to align device regulation across the region and cut down on duplicative requirements for manufacturers seeking access to multiple ASEAN markets. It does not replace national regulation: each member state enacts the AMDD through its own legislation and retains its own regulatory authority. Thailand implemented the framework through the Medical Device Act B.E. 2562 (2019), which substantially rebuilt Thailand's device regulatory system around the common ASEAN standard, and other member states have done the same at their own pace and with varying degrees of completeness. The practical upshot for manufacturers is that a technical dossier built to the ASEAN Common Submission Dossier Template (CSDT) standard, with a device classified under the AMDD's classification rules, can serve as the basis for registration applications across several ASEAN markets at once. National differences in application forms, labeling, local license holder requirements, and specific technical expectations still remain, but the core dossier content stays substantially common.

How the Four ASEAN Classes Map to Thailand's Three

The AMDD's classification framework uses four risk-based classes, A through D, and Thailand maps its own three-class national system onto that ASEAN structure rather than running a parallel scheme. ASEAN Class A, the lowest-risk tier, covers non-invasive devices with no patient contact or only superficial contact with intact skin, things like tongue depressors, non-sterile examination gloves, and simple bandages, and it generally lines up with Thailand's Class 1, notification-only category. ASEAN Class B covers devices with limited invasiveness or diagnostic devices carrying limited risk, such as powered wheelchairs, blood pressure monitors, non-active surgical instruments, and diagnostic ultrasound equipment, and this maps to Thailand's Class 2. ASEAN Class C, moderate-to-high risk, covers highly invasive devices, surgical implants, devices delivering substantial energy, or devices critical to patient survival, such as high-risk infusion pumps, long-term implantable bone screws, and X-ray equipment, generally landing in the upper tier of Thai Class 2 or in Class 3. ASEAN Class D, the highest tier, covers devices in direct contact with the heart or central nervous system or used to diagnose or treat life-threatening conditions in real time, such as pacemakers, cochlear implants, cardiac stents, and implantable neurostimulators, and these are uniformly Thai Class 3.

What Carries Across in the CSDT and What Stays National

The CSDT is the harmonized dossier format ASEAN member states adopted under the AMDD, and a CSDT built for one ASEAN country can generally be adapted for others by adjusting the national administrative sections while the technical content, device description, performance data, risk analysis, QMS documentation, and clinical evidence, stays substantially consistent. That technical content includes the device description and intended use, an Essential Principles of Safety and Performance checklist showing how the device meets each applicable principle with standards and summary evidence cited, a risk management summary built on ISO 14971, QMS documentation centered on an ISO 13485 certificate, and clinical evidence appropriate to the device's class: a clinical evaluation report for Class 2, and comprehensive clinical evidence from investigations or a systematic literature review for Class 3. The administrative section, by contrast, is the most country-specific part of the dossier and has to be rebuilt for each national submission, including the Local License Holder details that are unique to the Thai application.

Reliance Pathways Can Shorten the Thai Review

One of the genuine strategic benefits of AMDD harmonization is the reliance pathway, where a Thai FDA application can reference and build on a prior approval from another ASEAN regulator or a recognized stringent regulatory authority to streamline the Thai FDA review. This is not automatic; it requires explicit use and Thai FDA's agreement, but it is a real efficiency opportunity for manufacturers with existing ASEAN approvals. Singapore's Health Sciences Authority is the most commonly referenced ASEAN authority in these discussions, because Thai FDA has acknowledged HSA's review process as a reliable reference point; for a device with current HSA registration, Thai FDA may agree to an abridged review that relies on HSA's technical evaluation and focuses the Thai review on national differences like labeling and local entity requirements rather than re-evaluating all the technical data. CE marking under the EU Medical Device Regulation, or US FDA 510(k) clearance or PMA approval, can support an abridged Thai FDA review for certain device types as well, though availability and scope are worked out with Thai FDA case by case during pre-submission consultation.

Where Thailand Deviates From the Common Standard

Manufacturers relying on AMDD harmonization still need to identify Thailand's national deviations for every application. Thai-language labeling is required regardless of what other ASEAN countries accept, since the AMDD itself specifies no language requirement; this has to be addressed in the Thai administrative section of the CSDT on its own terms. Thailand also requires import permits for commercial device shipments, a step that runs in parallel to registration and is not uniformly required across every ASEAN member state, so manufacturers familiar only with the registration side of things can overlook it. Consumer-directed advertising for medical devices requires Thai FDA's prior approval as well, a nationally specific requirement outside the AMDD framework itself, meaning promotional material already approved in another ASEAN market still needs its own Thai FDA advertising clearance.

What This Means for a Regional Launch Strategy

The practical value of AMDD harmonization shows up most clearly in sequencing decisions. A manufacturer planning entry across several ASEAN markets is generally better served building the CSDT dossier once, to the full ASEAN standard, and then adapting the administrative sections per country, rather than building each national dossier independently from scratch. Where a manufacturer already holds CE marking or an HSA approval, sequencing the Thai FDA submission to lead with the reliance pathway, rather than defaulting to a full standalone review, can meaningfully shorten the Thai timeline, provided the pre-submission consultation with Thai FDA happens early enough to confirm the scope of reliance Thai FDA is prepared to grant for that device type. Waiting until after a full submission is already in review to raise the reliance question forfeits most of the benefit.

Manufacturers with existing CE marking or HSA approval can genuinely reduce the documentation burden and review timeline in Thailand by using the reliance pathway, but only if Thailand's national deviations are identified and addressed before the application goes in rather than discovered afterward. DeeMED Consulting works with manufacturers on Thai FDA device classification and CSDT strategy that maximizes what an existing ASEAN or SRA approval can carry into the Thai submission.